Long-term effects of aliskiren on blood pressure and the renin-angiotensin-aldosterone system in hypertensive hemodialysis patients

International Journal of Nephrology and Renovascular Disease

Volumn 5, Issue , 2012, Pages 45-51

  Morishita, Yoshiyuki ^a   Watanabe, Minami ^a   Hanawa, Shiho ^a   Iimura, Osamu ^b   Tsunematsu, Sadao ^c   Ishibashi, Kenichi ^d   Kusano, Eiji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Kumakura Clinic   (Japan)

^c Yuki Hospital   (Japan)

^d MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Aldosterone; Aliskiren; Angiotensin; Blood pressure; Hemodialysis patients; Long term effects; Renin

Indexed keywords

ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METHYLDOPA;

AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; LONG TERM CARE; MALE; PLASMA RENIN ACTIVITY; POST HOC ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT DURATION;

EID: 84859055115     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: 10.2147/ijnrd.s30203     Document Type: Article

References (21)

1. Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115(4): 291-297.
2. Collins AJ, Roberts TL, St Peter WL, Chen SC, Ebben J, Constantini E. United States Renal Data System assessment of the impact of the National Kidney Foundation-Dialysis Outcomes Quality Initiative guidelines. Am J Kidney Dis. 2002;39(4):784-795.
3. Herzog CA, Ma JZ, Collins AJ. Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified? Circulation. 2002;105(11):1336-1341.
4. Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension. 2009;53(5):860-866.
5. Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009;373(9668):1009-1015.
6. Blankestijn PJ, Ligtenberg G. Volume-independent mechanisms of hypertension in hemodialysis patients: clinical implications. Semin Dial. 2004;17(4):265-269.
7. Laragh JH. Renin profiling for diagnosis, risk assessment, and treatment of hypertension. Kidney Int. 1993;44(5):1163-1175.
8. Matsumoto N, Ishimitsu T, Okamura A, Seta H, Takahashi M, Matsuoka H. Effects of imidapril on left ventricular mass in chronic hemodialysis patients. Hypertens Res. 2006;29(4):253-260.
9. Wauters JP, Waeber B, Brunner HR, Guignard JP, Turini GA, Gavras H. Uncontrollable hypertension in patients on hemodialysis: long-term treatment with captopril and salt subtraction. Clin Nephrol. 1981;16(2): 86-92.
10. Saracho R, Martin-Malo A, Martinez I, Aljama P, Montenegro J. Evaluation of the Losartan in Hemodialysis (ELHE) Study. Kidney Int Suppl. 1998;68:S125-S129.
11. Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron. 2002;90(3):256-261.
12. Kanno Y, Kaneko K, Kaneko M, et al. Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol. 2004;43(3): 380-386.
13. Morishita Y, Kusano E. The blockade of renin-angiotensin-aldosterone system in hemodialysis patients to control hypertension and prevent cardiovascular disease: optimal pharmacotherapy. Cardiovasc Hematol Agents Med Chem. 2011. Epub Oct 21.
14. Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res. 2011;34(3):308-313.
15. Emanuel RL, Cain JP, Williams GH. Double antibody radioimmunoassay of renin activity and angiotensin II in human peripheral plasma. J Lab Clin Med. 1973;81(4):632-640.
16. Rodbard D. Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays. Clin Chem. 1974;20(10):1255-1270.
17. Cesarone MR, Belcaro G, Carratelli M, et al. A simple test to monitor oxidative stress. Int Angiol. 1999;18(2):127-130.
18. Gerardi G, Usberti M, Martini G, et al. Plasma total antioxidant capacity in hemodialyzed patients and its relationships to other biomarkers of oxidative stress and lipid peroxidation. Clin Chem Lab Med. 2002;40(2): 104-110.
19. Latini R, Masson S, Anand I, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004;25(4):292-299.
20. Latini R, Masson S, Wong M, et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med. 2006;119(1):70, e23-e30.
21. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptideguided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49(16):1733-1739.